Journal article
The BDNF Val66Met polymorphism moderates the relationship between Posttraumatic Stress Disorder and fear extinction learning
KL Felmingham, DV Zuj, KCM Hsu, E Nicholson, MA Palmer, K Stuart, JC Vickers, GS Malhi, RA Bryant
Psychoneuroendocrinology | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2018
Abstract
The low expression Met allele of the BDNF Val66Met polymorphism is associated with impaired fear extinction in healthy controls, and poorer response to exposure therapy in patients with Posttraumatic Stress Disorder (PTSD). Given that fear extinction underlies exposure therapy, this raises the question of the impact of BDNFVal66Met polymorphism on fear extinction in PTSD, yet this question has not yet been examined. One hundred and six participants (22 PTSD, 46 trauma-exposed controls (TC) and 38 non-trauma exposed controls (NTC)) completed a fear conditioning and extinction task and saliva samples were taken for DNA extraction and genotyped for the BDNF Val66Met polymorphism. Moderation ana..
View full abstractGrants
Awarded by American Foundation for Suicide Prevention
Funding Acknowledgements
The current research study is funded by the National Health and Medical Research Council (NHMRC). Gin S Malhi has received grant or research support from National Health and Medical Research Council, NSW Health, Ramsay Health, American Foundation for Suicide Prevention, AstraZeneca, Eli Lilly & Co, Organon, Pfizer, Servier, and Wyeth; has been a speaker for AstraZeneca, Eli Lilly & Co, Janssen Cilag, Lundbeck, Pfizer, Ranbaxy, Servier, and Wyeth; and has been a consultant for AstraZeneca, Eli Lilly & Co, Janssen Cilag, Lundbeck, and Servier. Professor's Felmingham, Bryant, and Vickers research is funded by the National Health and Medical Research Council (NHMRC) and Dr Palmer by the Australian Research Council, but these funding bodies have no involvement in the planning, acquisition and analysis, or publication of findings.